REGNÂ – Regeneron Pharmaceuticals, Inc.
Float Short %
2.81
Margin Of Safety %
14
Put/Call OI Ratio
0.48
EPS Next Q Diff
-1.42
EPS Last/This Y
2.32
EPS This/Next Y
-4.67
Price
703.26
Target Price
789.04
Analyst Recom
1.83
Performance Q
26.37
Relative Volume
0.86
Beta
0.39
Ticker: REGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | REGN | 654.72 | 0.51 | 0.80 | 55270 |
| 2025-11-11 | REGN | 674.63 | 0.51 | 0.40 | 55336 |
| 2025-11-12 | REGN | 683.37 | 0.51 | 0.48 | 55983 |
| 2025-11-13 | REGN | 695.33 | 0.51 | 0.32 | 56207 |
| 2025-11-14 | REGN | 693.49 | 0.51 | 0.31 | 57265 |
| 2025-11-17 | REGN | 704.42 | 0.50 | 0.49 | 56363 |
| 2025-11-18 | REGN | 725.64 | 0.50 | 0.30 | 56730 |
| 2025-11-19 | REGN | 702.96 | 0.50 | 0.06 | 57712 |
| 2025-11-20 | REGN | 737.79 | 0.53 | 0.57 | 56486 |
| 2025-11-21 | REGN | 755.54 | 0.55 | 0.33 | 57393 |
| 2025-11-24 | REGN | 761.42 | 0.43 | 0.47 | 52207 |
| 2025-11-25 | REGN | 787.75 | 0.44 | 0.34 | 53431 |
| 2025-11-26 | REGN | 783.61 | 0.44 | 0.95 | 54659 |
| 2025-12-01 | REGN | 749.84 | 0.44 | 0.49 | 54117 |
| 2025-12-02 | REGN | 741.55 | 0.46 | 1.27 | 54832 |
| 2025-12-03 | REGN | 722.27 | 0.47 | 0.78 | 55969 |
| 2025-12-04 | REGN | 722.79 | 0.48 | 2.32 | 57142 |
| 2025-12-05 | REGN | 718.26 | 0.48 | 1.40 | 57400 |
| 2025-12-08 | REGN | 703.1 | 0.48 | 1.46 | 56884 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | REGN | 654.74 | -11.5 | -1386.9 | 43.23 |
| 2025-11-11 | REGN | 674.55 | -11.7 | -1243.2 | 43.23 |
| 2025-11-12 | REGN | 682.12 | -11.7 | -1322.6 | 43.23 |
| 2025-11-13 | REGN | 694.94 | -11.7 | -1288.7 | 43.23 |
| 2025-11-14 | REGN | 693.25 | -11.7 | -1379.6 | 43.23 |
| 2025-11-17 | REGN | 704.23 | -11.7 | -1305.1 | 43.23 |
| 2025-11-18 | REGN | 725.62 | -12.2 | -1244.0 | 43.19 |
| 2025-11-19 | REGN | 702.75 | -12.2 | -1498.1 | 43.19 |
| 2025-11-20 | REGN | 737.71 | -12.2 | -1163.3 | 43.19 |
| 2025-11-21 | REGN | 755.54 | -12.1 | -1260.2 | 43.20 |
| 2025-11-24 | REGN | 761.58 | -12.1 | -1333.1 | 43.20 |
| 2025-11-25 | REGN | 787.32 | -10.9 | -1224.1 | 43.22 |
| 2025-11-26 | REGN | 784.81 | -10.9 | -1377.2 | 43.22 |
| 2025-12-01 | REGN | 750.02 | -10.9 | -1523.0 | 43.22 |
| 2025-12-02 | REGN | 742.00 | -10.9 | -1408.6 | 43.22 |
| 2025-12-03 | REGN | 723.67 | -10.9 | -1465.9 | 43.22 |
| 2025-12-04 | REGN | 722.91 | -10.9 | -1368.4 | 43.22 |
| 2025-12-05 | REGN | 718.36 | -10.9 | -1389.4 | 43.22 |
| 2025-12-08 | REGN | 703.26 | -10.9 | - | 43.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | REGN | -0.18 | -3.11 | 2.89 |
| 2025-11-11 | REGN | -0.18 | -3.11 | 2.89 |
| 2025-11-12 | REGN | -0.18 | -3.11 | 2.76 |
| 2025-11-13 | REGN | -0.18 | -3.11 | 2.76 |
| 2025-11-14 | REGN | -0.18 | -3.11 | 2.76 |
| 2025-11-17 | REGN | -0.18 | -2.14 | 2.76 |
| 2025-11-18 | REGN | -0.18 | -2.14 | 2.76 |
| 2025-11-19 | REGN | -0.18 | -2.14 | 2.76 |
| 2025-11-20 | REGN | -0.18 | -2.14 | 2.76 |
| 2025-11-21 | REGN | -0.18 | -2.14 | 2.76 |
| 2025-11-24 | REGN | -0.20 | -0.99 | 2.76 |
| 2025-11-25 | REGN | -0.20 | -0.99 | 2.76 |
| 2025-11-26 | REGN | -0.20 | -0.99 | 2.81 |
| 2025-12-01 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-02 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-03 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-04 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-05 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-08 | REGN | -0.20 | -0.98 | 2.81 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
11.83
Avg. EPS Est. Current Quarter
10.76
Avg. EPS Est. Next Quarter
10.41
Insider Transactions
-0.2
Institutional Transactions
-0.98
Beta
0.39
Average Sales Estimate Current Quarter
3745
Average Sales Estimate Next Quarter
3422
Fair Value
802.46
Quality Score
99
Growth Score
78
Sentiment Score
9
Actual DrawDown %
41.9
Max Drawdown 5-Year %
-59.7
Target Price
789.04
P/E
16.84
Forward P/E
15.9
PEG
3.33
P/S
5.19
P/B
2.39
P/Free Cash Flow
17.51
EPS
41.77
Average EPS Est. Cur. Y​
43.22
EPS Next Y. (Est.)
38.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
32.13
Relative Volume
0.86
Return on Equity vs Sector %
-12.1
Return on Equity vs Industry %
2.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15222
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading